My Pathway: An Open Label Phase IIa Study Evaluating Trastuzumab/Pertuzumab, Erlotinib, Vemurafenib/Cobimetinib, and Vismodegib in Patients Who Have Advanced Solid Tumors With Mutations or Gene Expression Abnormalities Predictive of Response to One of These Agents

Trial Profile

My Pathway: An Open Label Phase IIa Study Evaluating Trastuzumab/Pertuzumab, Erlotinib, Vemurafenib/Cobimetinib, and Vismodegib in Patients Who Have Advanced Solid Tumors With Mutations or Gene Expression Abnormalities Predictive of Response to One of These Agents

Recruiting
Phase of Trial: Phase II

Latest Information Update: 04 Apr 2018

At a glance

  • Drugs Alectinib (Primary) ; Atezolizumab (Primary) ; Cobimetinib (Primary) ; Erlotinib (Primary) ; Pertuzumab (Primary) ; Trastuzumab (Primary) ; Vemurafenib (Primary) ; Vismodegib (Primary)
  • Indications Solid tumours; Tumours
  • Focus Therapeutic Use
  • Acronyms Mypathway
  • Sponsors Genentech
  • Most Recent Events

    • 15 Jan 2018 According to results published in the Journal of Clinical Oncology, from April 1, 2014 to November 1, 2016, 251 patients with 35 different tumor types were enrolled from 38 centers in the United States.
    • 10 Jan 2018 Results assessing the efficacy in the first 230 treated patients who were efficacy evaluable, were published in the Journal of Clinical Oncology.
    • 10 Jun 2017 Biomarkers information updated
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top